Lisa A Cannon-Albright1,2,3, James M Farnham1, Jeffrey Stevens1, Craig C Teerlink1, Cheryl A Palmer3,4,5, Kerry Rowe6, Melissa H Cessna6,7, Deborah T Blumenthal8. 1. Genetic Epidemiology, University of Utah School of Medicine, Salt Lake City, Utah, USA. 2. George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, Utah, USA. 3. Huntsman Cancer Institute, Salt Lake City, Utah, USA. 4. Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA. 5. ARUP Laboratories, Salt Lake City, Utah, USA. 6. Intermountain Healthcare, Salt Lake City, Utah, USA. 7. Intermountain Biorepository and Department of Pathology, Intermountain Healthcare, Salt Lake City, Utah, USA. 8. Tel-Aviv Sourasky Medical Center, Tel-Aviv University, Tel-Aviv, Israel.
Abstract
BACKGROUND: There is evidence for an inherited contribution to primary brain cancer. Linkage analysis of high-risk brain cancer pedigrees has identified candidate regions of interest in which brain cancer predisposition genes are likely to reside. METHODS: Genome-wide linkage analysis was performed in a unique set of 11 informative, extended, high-risk primary brain cancer pedigrees identified in a population genealogy database, which include from 2 to 6 sampled, related primary brain cancer cases. Access to formalin-fixed paraffin embedded tissue samples archived in a biorepository allowed analysis of extended pedigrees. RESULTS: Individual high-risk pedigrees were singly informative for linkage at multiple regions. Suggestive evidence for linkage was observed on chromosomes 2, 3, 14, and 16. The chromosome 16 region in particular contains a promising candidate gene, pyridoxal-dependent decarboxylase domain-containing 1 (PDXDC1), with prior evidence for involvement with glioblastoma from other previously reported experimental settings, and contains the lead single nucleotide polymorphism (rs3198697) from the linkage analysis of the chromosome 16 region. CONCLUSIONS: Pedigrees with a statistical excess of primary brain cancers have been identified in a unique genealogy resource representing the homogeneous Utah population. Genome-wide linkage analysis of these pedigrees has identified a potential candidate predisposition gene, as well as multiple candidate regions that could harbor predisposition loci, and for which further analysis is suggested.
BACKGROUND: There is evidence for an inherited contribution to primary brain cancer. Linkage analysis of high-risk brain cancer pedigrees has identified candidate regions of interest in which brain cancer predisposition genes are likely to reside. METHODS: Genome-wide linkage analysis was performed in a unique set of 11 informative, extended, high-risk primary brain cancer pedigrees identified in a population genealogy database, which include from 2 to 6 sampled, related primary brain cancer cases. Access to formalin-fixed paraffin embedded tissue samples archived in a biorepository allowed analysis of extended pedigrees. RESULTS: Individual high-risk pedigrees were singly informative for linkage at multiple regions. Suggestive evidence for linkage was observed on chromosomes 2, 3, 14, and 16. The chromosome 16 region in particular contains a promising candidate gene, pyridoxal-dependent decarboxylase domain-containing 1 (PDXDC1), with prior evidence for involvement with glioblastoma from other previously reported experimental settings, and contains the lead single nucleotide polymorphism (rs3198697) from the linkage analysis of the chromosome 16 region. CONCLUSIONS: Pedigrees with a statistical excess of primary brain cancers have been identified in a unique genealogy resource representing the homogeneous Utah population. Genome-wide linkage analysis of these pedigrees has identified a potential candidate predisposition gene, as well as multiple candidate regions that could harbor predisposition loci, and for which further analysis is suggested.
Authors: Craig C Teerlink; Chad Huff; Jeff Stevens; Yao Yu; Sheri L Holmen; Mark R Silvis; Kirby Trombetti; Hua Zhao; Douglas Grossman; James M Farnham; Jingran Wen; Julio C Facelli; Alun Thomas; Markus Babst; Scott R Florell; Laurence Meyer; John J Zone; Sancy Leachman; Lisa A Cannon-Albright Journal: J Natl Cancer Inst Date: 2018-12-01 Impact factor: 13.506
Authors: Sanjay Shete; Ching C Lau; Richard S Houlston; Elizabeth B Claus; Jill Barnholtz-Sloan; Rose Lai; Dora Il'yasova; Joellen Schildkraut; Siegal Sadetzki; Christoffer Johansen; Jonine L Bernstein; Sara H Olson; Robert B Jenkins; Ping Yang; Nicholas A Vick; Margaret Wrensch; Faith G Davis; Bridget J McCarthy; Eastwood Hon-chiu Leung; Caleb Davis; Rita Cheng; Fay J Hosking; Georgina N Armstrong; Yanhong Liu; Robert K Yu; Roger Henriksson; Beatrice S Melin; Melissa L Bondy Journal: Cancer Res Date: 2011-10-28 Impact factor: 12.701
Authors: Niina Paunu; Päivi Lahermo; Päivi Onkamo; Vesa Ollikainen; Immo Rantala; Pauli Helén; Kalle O J Simola; Juha Kere; Hannu Haapasalo Journal: Cancer Res Date: 2002-07-01 Impact factor: 12.701
Authors: A Kamb; D Shattuck-Eidens; R Eeles; Q Liu; N A Gruis; W Ding; C Hussey; T Tran; Y Miki; J Weaver-Feldhaus Journal: Nat Genet Date: 1994-09 Impact factor: 38.330
Authors: Craig C Teerlink; Jeff Stevens; Rolando Hernandez; Julio C Facelli; Lisa A Cannon-Albright Journal: Cancer Epidemiol Date: 2021-04-28 Impact factor: 2.890